



Health Canada Authorizes Emerald Health to Sell Cannabis Oil

VICTORIA, BC, July 12, 2016 – Emerald Health Therapeutics Inc. (TSXV: EMH) ("Therapeutics") is pleased to announced that its wholly owned subsidiary, Emerald Health Botanicals Inc. ("Botanicals"), has received a Supplemental Licence from Health Canada authorizing Botanicals to sell cannabis oils. Botanicals expects to launch its suite of cannabis oil products shortly, which will include THCA (Tetrahydrocannabinolic acid) oil, THC oil, as well as oils containing both THC and CBD.

From its research program funded by National Research Council of Canada-IRAP grants, the Botanicals team has characterized several new strains from its diverse pool of cannabis seeds. Strains with exceptionally high CBD levels will allow Botanicals to produce CBD oils with unique compositions of cannabinoids through blending.

"As life science professionals we are excited about being able to offer our clients medical cannabis in a form that can be precisely dosed and ingested. Our patients will now be able to access the benefits of medicinal cannabis through a wider range of routes of administration." stated Dr. Avtar Dhillon, Chairman of Therapeutics.

ON BEHALF OF THE BOARD

"Dr. Bin Huang"

CEO

Emerald Health Therapeutics Inc.

Therapeutics wholly owns Botanicals, which has been granted licences under the *Marihuana for Medical Purposes Regulations* to cultivate and sell medical cannabis, and to produce and sell medical cannabis oils in Canada.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".

We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including production and sales of cannabis oils, the type of cannabis oils to be produced, the anticipated benefits of the cannabis oils, when Therapeutics may begin selling cannabis oils and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Emerald Health Therapeutics Inc. does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, the ability of the Therapeutics and Botanicals to produce cannabis oil to be sold to customers. Actual results may differ materially from those expressed or implied by such forward-looking statements.

For further information: Please contact Emerald Health Therapeutics CFO, Sandy Pratt, at 250-818-9838 or sandy@emerald.care.